《复牌公告》石四药(02005.HK)不保证阿比多尔获纳入武汉肺炎诊疗方案
石四药集团(02005.HK)就股份成交量及股价不寻常波动声明,相信乃由於近日传媒新闻报道所致。据报道指,中国工程院院士、国家卫健委高级别专家成员李兰娟在武汉公布治疗新型冠状病毒(2019-nCoV)感染肺炎的最新研究成果,建议将阿比多尔和达芦那韦列入国家卫健委《新型冠状病毒感染的肺炎诊疗方案(试行第六版)》。集团拥有在中国生产阿比多尔原料药及制剂之领先公司。
董事相信,至今,传媒新闻所报道有关李兰娟之建议尚未经国家卫健委确认采纳或列入国家卫健委《新型冠状病毒感染的肺炎诊疗方案(试行第六版)》,而公司不能保证上述者即将落实,甚或不会落实。
公司股份申请周四(6日)恢复买卖。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.